Exagen Q3 revenue $12.5M (-7% YoY); ASP up 26%; net loss improves 37% YTD

EXAGEN INC.

2024-Q3 EPS reported -$0.63 revenue$41,986,000

Q3 2024 revenue $12.5M, down from $13.4M in Q3 2023, impacted by $1.2M one-time adjustments.
AVISE CTD trailing twelve-month ASP $404, up 26% from $320 a year ago.
Net loss first nine months 2024 improved 37% to $11.4M from $18.1M; adj. EBITDA loss improved 42% to $7.6M.
Cash and equivalents $22.0M at Sept 30; net cash burn $2.5M in Q3.
Completed validation for new biomarkers, submitted to NY State; appointed Jeff Black as CFO effective Sept 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.